Carregant...

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

BACKGROUND: The aim of our retrospective study was to evaluate the 5-year survival and time to castration resistant prostate cancer in patients with hormone sensitive prostate cancer treated with the gonadotropin releasing hormone antagonist, degarelix. Another aim was to evaluate the effects of cha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Basic Clin Androl
Autors principals: Asakawa, Jumpei, Iguchi, Taro, Tamada, Satoshi, Yasuda, Sayaka, Ninomiya, Noriko, Kato, Minoru, Yamasaki, Takeshi, Ohmachi, Tetusji, Nakatani, Tatsuya
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6050721/
https://ncbi.nlm.nih.gov/pubmed/30026950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12610-018-0074-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!